Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL35533/0103.
Eyzeetan 0.3mg/ml + 5mg/ml Eye Drops, Solution
eyzeetan 0.3mg/ml + 5mg/ml Eye Drops, Solution
Bimatoprost/Timolol
Eyzeetan Eye Drops are contained within a novel multi-dose eye drop bottle, which allows for the solution not to contain any preservatives. Due to the design of the container, administration with these eye drops is not the same as standard eye drop bottles.
Please read the full instructions on the correct use of this product in Section 3 of the leaflet (‘‘How to use Eyzeetan’’), before using these eye drops.
1. What Eyzeetan is and what it is used for
2. What you need to know before you use Eyzeetan
3. How to use Eyzeetan
4. Possible side effects
5. How to store Eyzeetan
6. Contents of the pack and other information
Eyzeetan contains two different active substances (bimatoprost and timolol) that both reduce pressure in the eye. Bimatoprost belongs to a group of medicines called prostamides, which are prostaglandin analogues. Timolol belongs to a group of medicines called beta-blockers.
Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid is constantly being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up and could eventually damage your sight (an illness called glaucoma). Eyzeetan works by reducing the production of liquid and also increasing the amount of liquid that is drained. This reduces the pressure inside the eye.
Eyzeetan eye drops are used to treat high pressure in the eye in adults, including the elderly. This high pressure can lead to glaucoma. Your doctor will prescribe you Eyzeetan when other eye drops containing beta-blockers or prostaglandin analogues have not worked sufficiently on their own.
Eyzeetan eye drops solution is a sterile solution that does not contain a preservative.
Talk to your doctor before using Eyzeetan if you have now or have had in the past:
If you have a history of contact hypersensitivity to silver, you should not use this product as dispensed drops may contain traces of silver.
Tell your doctor before surgical anaesthesia that you are using Eyzeetan as timolol may change effects of some medicines used during anaesthesia.
During treatment, Eyzeetan may cause a loss of fat around the eye, which may cause your eyelid crease to deepen, your eye to appear sunken (enophthalmos), your upper eyelid to droop (ptosis), the skin around your eye to tighten (involution of dermatochalasis) and the lower white part of your eye to become more visible (inferior scleral show). The changes are typically mild, but if pronounced, they can affect your field of vision. The changes may disappear if you stop taking Eyzeetan. Eyzeetan may also cause your eyelashes to darken and grow, and cause the skin around the eye to darken too. The colour of your iris may also go darker. These changes may be permanent.
The change may be more noticeable if you are only treating one eye. Eyzeetan may cause hair growth when in contact with the skin surface.
Eyzeetan should not be used in children and teenagers under 18.
Eyzeetan can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Tell your doctor if you are using or intend to use:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not use Eyzeetan if you are pregnant unless your doctor still recommends it.
Do not use Eyzeetan if you are breast-feeding. Timolol may get into your breast milk.
Ask your doctor for advice before taking any medicine during breast-feeding.
Eyzeetan may cause blurred vision in some patients. Do not drive or use machines until the symptoms have cleared.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one drop once a day, either in the morning or in the evening in each eye that needs treatment. Use at the same time each day.
Do not allow the tip of the multi-dose container to touch the eye or areas around the eye. It could cause injury to your eye. The eye drops solution may become contaminated with bacteria that can cause eye infections leading to serious damage of the eye, even loss of vision.
To avoid possible contamination of the multi-dose container, keep the tip of the multi-dose container away from contact with any surface.
Before instillation of the eye drops:
1. Hold the bottle directly below the cap and turn the cap to open the bottle. Do not touch anything with the tip of the bottle to avoid contamination of the solution.
2. Tilt your head backwards and hold the bottle above your eye.
3. Pull the lower eyelid down and look up. Squeeze the bottle gently in the middle and let a drop fall into your eye. Please note that there might be a few seconds delay between squeezing and the drop coming out. Do not squeeze too hard. If a drop misses your eye, try again.
If you are not sure how to administer your medicine, ask your doctor, pharmacist or nurse.
4. Blink a few times so that the drop spreads over the eye.
5. After using Eyzeetan, press a finger into the corner of your eye, by the nose, for 2 minutes. This helps to stop Eyzeetan getting into the rest of your body.
6. Repeat the instructions 2. – 5. to deliver a drop into the other eye also, if your doctor has instructed you to do this. Sometimes only one eye needs to be treated and your doctor will advise if this applies to you and which eye needs treatment.
7. After use and prior to recapping, the bottle should be shaken once in a downwards direction, without touching the dropper tip, in order to remove any residual liquid on the tip. This is necessary in order to ensure delivery of subsequent drops.
8. After you have used all doses there will be some Eyzeetan left in the bottle. You should not be concerned since an extra amount of Eyzeetan has been added and you will get the full amount of Eyzeetan that your doctor has prescribed. Do not attempt to use the excess medicine remaining in the bottle after you have completed the course of treatment.
Do not use the eye drops for longer than 28 days after first opening the bottle.
If you use Eyzeetan with another eye medicine, leave at least 5 minutes between putting in Eyzeetan and the other medicine. Use any eye ointment or eye gel last.
If you use more Eyzeetan than you should, it is unlikely to cause you any serious harm. Put your next dose in at the usual time. If you are worried, talk to your doctor or pharmacist.
If you forget to use Eyzeetan, use a single drop as soon as you remember, and then go back to your regular routine. Do not use a double dose to make up for a forgotten dose.
Eyzeetan should be used every day to work properly.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, Eyzeetan can cause side effects, although not everybody gets them.
You can usually carry on taking the drops, unless the effects are serious. If you’re worried, talk to a doctor or pharmacist. Do not stop using Eyzeetan without speaking to your doctor.
The following eye side effects may be seen with Eyzeetan:
Very common (may affect more than 1 in 10 people):
Affecting the eye
Affecting the eye region
Common (may affect up to 1 in 10 people):
Affecting the eye
Affecting other parts of the body
Uncommon (may affect up to 1 in 100 people):
Affecting the eye
Affecting other parts of the body
Not known (frequency cannot be estimated from available data):
Affecting the eye
Affecting other parts of the body
Additional side effects have been seen in patients using eye drops containing timolol or bimatoprost and so may possibly be seen with Eyzeetan. Like other medicines applied into eyes, timolol is absorbed into the blood. This may cause similar side effects as seen with “intravenous” and/or “oral” beta-blocking agents. The chance of having side effects after using eye drops is lower than when medicines are for example, taken by mouth or injected. Listed side effects include reactions seen within the class of beta-blockers when used for treating eye conditions:
This medicine contains 4.74mg phosphates in each 5ml of solution which is equivalent to 0.95mg/ml. If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme (website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store).
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle label and the carton after EXP. The expiry date refers to the last day of that month.
Store below 30°C. After first opening, the product may be stored for a maximum of 28 days.
Do not use this medicine if you notice that the seal is broken the first time you use the bottle.
Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Eyzeetan is presented as a clear, colourless aqueous solution filled in a white opaque 5ml LDPE bottle and white Novelia nozzle (HDPE and silicone) with a blue tip and sealed with a white HDPE cap.
Pack sizes: 1 or 3 bottles in a cardboard box.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
and
This leaflet was last revised in 01/2023
1010421-P7.5